Cancer Studies
Cancer Cell Mechanisms
- Molecular cytogenetics of lymphoid malignancies
- Antibody therapy of lymphoid malignancies
- Development and assessment of novel agents for therapy of B-cell malignancies
- Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers
- Receptor tyrosine kinase AXL as a biomarker in diagnostic and treatment of bladder cancer
- Molecular biology of early lung malignancy
- Cell biological interpretation of tumour morphology and cytology
- Translational dysregulation as a predictive biomarker
- Mechanisms of RAS/RAF oncogene induced tumour development
- RAF/MAPK signalling in normal and cancer cells
- Ex vivo patient relevant drug testing platforms
Dr Eugene Tulchinsky
- Molecular Mechanisms of Epithelial Mesenchymal Transition in Cancer
- Translation regulation and lymphoproliferative disease
- T-cell lymphoma genetics and function
- Analysis of circulating cancer biomarkers through liquid biopsy
- Molecular approaches to aid early detection of cancer
- Molecular mechanisms of resistance to targeted therapy
Chemoprevention
- Preclinical and early clinical development of novel cancer chemopreventive agents
- Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy
Professor Don J. L. Jones
- Translation of candidate biomarkers to clinical use.
- Use of high resolution LC-MS in the discovery and verification of biomarkers.
- Investigation of protein quantification using Ion mobility.
Dr Alessandro Rufini
- Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol.
- Investigating and exploiting metabolic vulnerabilities in carcinogenesis .
- Using circulating cell-free DNA for early detection of cancer
Professor Anne Thomas
- The design and delivery of early phase clinical studies including chemoprevention strategies
- Improving information exchange in oncology consultations
Early Detection
- Analysis of circulating cancer biomarkers through liquid biopsy
- Molecular approaches to aid early detection of cancer
- Molecular mechanisms of resistance to targeted therapy
- Molecular biology of early lung malignancy
- Cell biological interpretation of tumour morphology and cytology
- Translational dysregulation as a predictive biomarker
- Combined molecular and morphological characterisation of early lung adenocarcinoma.Histological grading characteristics of lung adenocarcinoma with prognostic relevance
- Assessment of the use of next generation sequencing for use as a diagnostic tool in tumours of uncertain origin
- Identification of biomarkers of genomic instability, clinical implications and relevance to tumour biology and behaviour
- Predicting melanoma treatment using circulating free DNA
- Identification and translation of melanoma tissue biomarkers
Personalised Medicine
- Development methods and biomarkers for the accurate measurement of radiogenic, oxidative and drug-induced DNA damage in vitro and in vivo
- Investigation of mechanisms and agents to increase DNA damage as a means of enhancing cancer cell treatment sensitivity
- Preclinical and clinical development of novel anti-cancer genotoxic agents
- Imaging applications to monitor drug therapy
- Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT
- Molecular cytogenetics of lymphoid malignancies
- Antibody therapy of lymphoid malignancies
- Development and assessment of novel agents for therapy of B-cell malignancies
- Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers
- The design and delivery of early phase clinical studies including chemoprevention strategies
- Improving information exchange in oncology consultations
- PD-L1, PD-1 and other markers of the stroma or malignant T-cells in T-cell lymphoma